Product Information
CILOSTAZOL 50 MG TABLET is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $0.1304 per EA under NDC 00093206506. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Nov 24, 2004. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Cilostazol market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
50 mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00093206506
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CILOSTAZOLApproval Type
Generic (ANDA)
FDA Application
ANDA077027FDA Approved
11/24/2004
TE Code
AB
On Market Since
4/24/2012
Pharmacological Classes
Price Statistics
The NADAC for CILOSTAZOL 50 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 12.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1304 per EA |
|---|---|
| All-time high | $0.1612 (May 11, 2016) |
| All-time low | $0.1008 (May 22, 2024) |
| 52-week high | $0.1304 |
| 52-week low | $0.1077 |
| Median price | $0.1198 |
| Average price | $0.1234 |
| Largest weekly change | +25.1% (Feb 21, 2024) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Cilostazol market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Cilostazol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Phosphodiesterase 3 Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CILOSTAZOL 50 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for CILOSTAZOL 50 MG TABLET, manufactured by Teva Pharmaceuticals USA Inc., is $0.1304 per EA (NDC 00093206506), effective Sep 30, 2026.
How has the price of CILOSTAZOL 50 MG TABLET changed over time?
Over the history we have for it, the NADAC for CILOSTAZOL 50 MG TABLET has declined 12.5%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for CILOSTAZOL 50 MG TABLET?
Since Nov 28, 2013, the NADAC for CILOSTAZOL 50 MG TABLET has ranged from a low of $0.1008 (May 22, 2024) to a high of $0.1612 (May 11, 2016), with a median of $0.1198 per EA.
Are there cheaper alternatives to CILOSTAZOL 50 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of CILOSTAZOL 50 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CILOSTAZOL 50 MG TABLET?
CILOSTAZOL 50 MG TABLET (NDC 00093206506) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.